U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO.ClH
Molecular Weight 201.693
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Pseudoephedrine hydrochloride

SMILES

Cl.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1

InChI

InChIKey=BALXUFOVQVENIU-KXNXZCPBSA-N
InChI=1S/C10H15NO.ClH/c1-8(11-2)10(12)9-6-4-3-5-7-9;/h3-8,10-12H,1-2H3;1H/t8-,10+;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

CNS Activity

Originator

Ladenburg, A.
4
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.6 µM [IC50]
Inhibitor
8297
 1.18 µM [IC50]
Agonist
2678
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
unhealthy, 38.8 years
n = 38
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51209
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51209
ZINC
ZINC000000020259
http://zinc15.docking.org/substances/ZINC000000020259
eMolecules
494893
https://www.emolecules.com/cgi-bin/more?vid=494893
PubMed

PubMed

TitleDatePubMed
A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis.
1975 Jan
Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: case report.
1999 Mar-Apr
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Angle closure risk from proprietary medicines.
2001 Apr
Mass spectrometric quantitation of chiral drugs by the kinetic method.
2001 Apr 15
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry.
2001 Apr 20
Ischaemic colitis on pseudoephedrine.
2001 Aug
Hypokalemic metabolic acidosis attributed to cough mixture abuse.
2001 Aug
A fast and efficient determination of amines and preservatives in cough and cold liquid and suspension formulations using a single isocratic ion-pairing high performance [correction of power] liquid chromatography method.
2001 Aug
Aziridine ring-opening reactions with chiral enolates. Stereocontrolled synthesis of 5-substituted-3-methyl-pyrrolidin-2-ones.
2001 Aug 24
Effect of organic cations on the renal tubular secretion of pseudoephedrine in the rat.
2001 Jan-Feb
Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherche Rhin Rhĵne Alpes Genève pour la transplantation d'Ilots de Langerhans.
2001 Jul
Cold-syrup induced movement disorder.
2001 Jun
Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations.
2001 Jun
Asymmetric synthesis of beta-substituted alpha-methyl-beta-amino esters by Mannich reaction of (S,S)-(+)-pseudoephedrine acetamide derived enolate with imines.
2001 Mar 8
Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine.
2001 Mar-Apr
Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man.
2001 May
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.
2001 May
Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
2001 May
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
2001 Nov
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol.
2001 Oct
Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry.
2001 Sep
Toxicity of over-the-counter cough and cold medications.
2001 Sep
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations.
2001 Sep
Simultaneous quantitation of ephedrines in urine by gas chromatography-nitrogen-phosphorus detection for doping control purposes.
2001 Sep 5
Generalized dermatitis due to pseudoephedrine.
2002 Aug
Evaluation of a pseudoephedrine linker for asymmetric alkylations on solid phase.
2002 Dec 26
Immediate hypersensitivity due to pseudoephedrine.
2002 Jan
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.
2002 Jun
Oral medications.
2002 Mar
[Bacteremia caused by coagulase-negative staphylococci: incidence, frequency of teicoplanin resistance and molecular epidemiology].
2002 Nov
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
Enhanced enantio- and diastereoselectivity via confinement and cation binding: yang photocyclization of 2-benzoyladamantane derivatives within zeolites.
2002 Nov 29
[Blood supply of the lips].
2002 Oct
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients].
2002 Oct
Enzymatic (R)-phenylacetylcarbinol production in benzaldehyde emulsions.
2002 Oct
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital].
2003 Apr
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003 Apr 14
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
2003 Jan
Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study.
2003 Jan
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003 Jul
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction.
2003 Jul 5
Safety of selegiline with cold medications.
2003 Mar
Adrenaline given outside the context of life threatening allergic reactions.
2003 Mar 15
Canine model of nasal congestion and allergic rhinitis.
2003 May
Patents

Patents

05560921
4
06835559
6
07888040
4
JP2002316927A
5
JP2002332229A
4
JP2003089638A
4
JP2007176958A
4
JP2007525670A
148
JP2008081510A
4
JP2008510795A
76
JP2010241834A
9
JP2010270109A
4
JP3553083B2
49
JPH02134A
4
JPS62221625A
4

Sample Use Guides

In Vivo Use Guide
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Name Type Language
Pseudoephedrine hydrochloride
EP   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ALLEGRA-D
Common Name English
ACTAHIST COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
CODIMAL-L.A. 12 COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
BROMANATE DM COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ALLERFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
RHINALAIR
Brand Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF HISTAFED
Common Name English
SINE-AID IB COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ALEVE-D
Common Name English
TRIACIN-C COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
TRIPHED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
MYFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF CODIMAL-L.A. 12
Common Name English
HISTAFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF CHILDREN'S ADVIL COLD
Common Name English
ALLEGRA-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ACTIFED
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF SINE-AID IB
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF BROMANATE DM
Common Name English
TRILITRON COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ADVIL ALLERGY SINUS
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [MART.]
Common Name English
CORPHED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF TRIPHED
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ZYRTEC-D
Common Name English
GALSUD
Brand Name English
DIMETANE-DX COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF TRILITRON
Common Name English
SEMPREX-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
CHILDREN'S ADVIL COLD COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
SUDAFED
Brand Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USP-RS]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [MI]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USAN]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF MYFED
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF BROMFED-DM
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF DIMETANE-DX
Common Name English
HYCOFENIX COMPONENT OF PSEUDOEPHEDRINE HYDROCHLORIDE
Brand Name English
OTRINOL
Brand Name English
ZYRTEC-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
NSC-33634
Code English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF TRIACIN-C
Common Name English
BROMFED-DM COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
Pseudoephedrine hydrochloride [WHO-DD]
Common Name English
CHILDREN'S MOTRIN COLD COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ALLERFED
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF MUCINEX D
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [VANDF]
Common Name English
EFIDAC 24
Brand Name English
PSEUDOEPHEDRINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF CHILDREN'S MOTRIN COLD
Common Name English
PSEUDOEPHEDRINE HCL
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ISOCLOR
Common Name English
MUCINEX D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF SEMPREX-D
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF ACTAHIST
Common Name English
ADVIL ALLERGY SINUS COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ALEVE-D COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
ACTIFED COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF HYCOFENIX
Brand Name English
GALPSEUD
Brand Name English
ISOCLOR COMPONENT PSEUDOEPHEDRINE HYDROCHLORIDE
Common Name English
PSEUDOEPHEDRINE HYDROCHLORIDE COMPONENT OF CORPHED
Common Name English
NSC-106567
Code English
Classification Tree Code System Code
NCI_THESAURUS C29709
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
CFR 21 CFR 341.20
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
DEA NO. 8112
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
Code System Code Type Description
NSC
106567
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
DAILYMED
6V9V2RYJ8N
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
SMS_ID
100000092030
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
EVMPD
SUB04119MIG
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
RS_ITEM_NUM
1581005
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
NCI_THESAURUS
C29390
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID10889343
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
CAS
345-78-8
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
RXCUI
91168
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY RxNorm
NSC
33634
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-462-1
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
DRUG BANK
DBSALT000149
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
PUBCHEM
9581
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
FDA UNII
6V9V2RYJ8N
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY
MERCK INDEX
m9294
Created by admin on Sat Dec 16 19:06:44 GMT 2023 , Edited by admin on Sat Dec 16 19:06:44 GMT 2023
PRIMARY Merck Index
ACTIVE MOIETY
Structure of PSEUDOEPHEDRINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966